Polycystic ovary syndrome has been renamed polyendocrine metabolic ovarian syndrome, or PMOS, to better reflect its complex hormonal nature [1].
The change aims to shift the medical understanding of the condition away from a purely gynecological focus. By emphasizing the endocrine and metabolic components, health providers hope to improve screening processes, and the overall quality of patient care [2, 3].
Endocrinologist Helena Teede said the name change on May 12, 2026 [1] during the European Congress of Endocrinology in Prague, Czech Republic [1]. The rebranding addresses a long-standing misconception that the condition is solely a disease of the ovaries [2].
Medical experts said the previous name, PCOS, failed to capture the systemic impact of the disorder. The new designation, PMOS, explicitly identifies the polyendocrine and metabolic aspects that drive the symptoms [4, 5]. This shift is intended to encourage a multidisciplinary approach to treatment, involving both endocrinologists and gynecologists to manage the patient's health more holistically [5].
The transition to PMOS is designed to reduce diagnostic delays by alerting clinicians to look for metabolic markers beyond the presence of ovarian cysts [3]. Experts said that highlighting the metabolic dimension is critical for preventing long-term complications associated with the syndrome [4].
The announcement in Prague marks a landmark shift in how the global medical community categorizes the disorder [4]. By correcting the terminology, the medical community seeks to ensure that patients receive comprehensive care that addresses hormonal imbalances, and metabolic risks alongside reproductive health [2, 5].
“Polycystic ovary syndrome has been renamed polyendocrine metabolic ovarian syndrome.”
The transition from PCOS to PMOS represents a fundamental shift in clinical framing. By moving the terminology from a descriptive anatomical observation (cysts on ovaries) to a functional systemic description (endocrine and metabolic dysfunction), the medical community is prioritizing the underlying causes over the visible symptoms. This likely leads to earlier intervention for metabolic risks, such as insulin resistance, and a more integrated care model that transcends a single medical specialty.
